Carregant...
Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
Sodium-glucose co-transporter 2 inhibitors (SGLT2is) such as dapagliflozin, canagliflozin, and empagliflozin, are a promising new therapy in the treatment of type 2 diabetes mellitus (T2DM). SGLT2is can effectively reduce hyperglycemia thus improving glycemic control and they offer some beneficial e...
Guardat en:
| Publicat a: | Cureus |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Cureus
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5716679/ https://ncbi.nlm.nih.gov/pubmed/29226041 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.1751 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|